Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis
Author:
Funder
Cancer Hospital Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference39 articles.
1. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012
2. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors;Das;J. Immunother. Cancer,2019
3. Meta-analysis in clinical trials revisited;DerSimonian;Conte Clin. Trials,2015
4. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma;Doki;N. Engl. J. Med.,2022
5. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion;Dong;Nat. Med.,2002
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis;Cancer Medicine;2024-03-30
2. Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation;Therapeutic Advances in Gastroenterology;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3